HK1206246A1 - Use of high dose laquinimod for treating multiple sclerosis (laquinimod) - Google Patents
Use of high dose laquinimod for treating multiple sclerosis (laquinimod)Info
- Publication number
- HK1206246A1 HK1206246A1 HK15106789.5A HK15106789A HK1206246A1 HK 1206246 A1 HK1206246 A1 HK 1206246A1 HK 15106789 A HK15106789 A HK 15106789A HK 1206246 A1 HK1206246 A1 HK 1206246A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- laquinimod
- multiple sclerosis
- high dose
- treating multiple
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261641389P | 2012-05-02 | 2012-05-02 | |
PCT/US2013/039090 WO2013166166A1 (en) | 2012-05-02 | 2013-05-01 | Use of high dose laquinimod for treating multiple sclerosis |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1206246A1 true HK1206246A1 (en) | 2016-01-08 |
Family
ID=49514859
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15106789.5A HK1206246A1 (en) | 2012-05-02 | 2015-07-16 | Use of high dose laquinimod for treating multiple sclerosis (laquinimod) |
Country Status (21)
Country | Link |
---|---|
US (3) | US20130303569A1 (ko) |
EP (1) | EP2844255A4 (ko) |
JP (2) | JP2015515985A (ko) |
KR (1) | KR20150013658A (ko) |
CN (2) | CN105832733A (ko) |
AR (1) | AR090885A1 (ko) |
AU (1) | AU2013256352A1 (ko) |
BR (1) | BR112014027010A2 (ko) |
CA (1) | CA2870684A1 (ko) |
CL (1) | CL2014002935A1 (ko) |
EA (1) | EA201492010A1 (ko) |
HK (1) | HK1206246A1 (ko) |
IL (1) | IL235337A0 (ko) |
MX (1) | MX2014013039A (ko) |
PE (1) | PE20150161A1 (ko) |
PH (1) | PH12014502447A1 (ko) |
SG (1) | SG11201406594UA (ko) |
TW (2) | TW201347762A (ko) |
UY (1) | UY34775A (ko) |
WO (1) | WO2013166166A1 (ko) |
ZA (1) | ZA201408820B (ko) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014530821A (ja) | 2011-10-12 | 2014-11-20 | テバ ファーマシューティカル インダストリーズ リミティド | ラキニモドおよびフィンゴリモドを組み合わせた多発性硬化症の治療 |
TW201345527A (zh) | 2012-02-03 | 2013-11-16 | Teva Pharma | 拉喹莫德於治療對第一線抗-TNFα療法無效之克隆氏症患者之用途 |
AU2013221304B2 (en) | 2012-02-16 | 2017-12-21 | Teva Pharmaceutical Industries Ltd. | N-ethyl-N-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinoline carboxamide, preparation and uses thereof |
US20130259856A1 (en) * | 2012-03-27 | 2013-10-03 | Teva Pharmaceutical Industries, Ltd. | Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate |
TW201400117A (zh) | 2012-06-05 | 2014-01-01 | Teva Pharma | 使用拉喹莫德治療眼發炎疾病 |
TW201410244A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療gaba媒介之疾病之拉喹莫德(laquinimod) |
EA201590726A1 (ru) * | 2012-10-12 | 2015-10-30 | Тева Фармасьютикал Индастриз Лтд. | Лахинимод для уменьшения таламического поражения при рассеянном склерозе |
EP2916915A4 (en) | 2012-11-07 | 2016-06-22 | Teva Pharma | LAQUINIMOD AMINE SALTS |
CN105163737A (zh) * | 2013-02-15 | 2015-12-16 | 梯瓦制药工业有限公司 | 用拉喹莫德治疗多发性硬化症 |
MX2015011627A (es) | 2013-03-14 | 2016-05-16 | Teva Pharma | Cristales de laquinimod sodico y proceso mejorado para la elaboracion de los mismos. |
AR098924A1 (es) * | 2013-12-23 | 2016-06-22 | Teva Pharma | Tratamiento de la esclerosis múltiple con una combinación de laquinimod y teriflunomida |
UY36099A (es) * | 2014-04-29 | 2016-02-29 | Teva Pharma | Laquinimod para el tratamiento de pacientes con esclerosis múltiple remitente recurrente (rrms) con un alto grado de discapacidad |
WO2017027512A1 (en) * | 2015-08-13 | 2017-02-16 | Teva Pharmaceutical Industries Ltd. | Use of laquinimod to treat traumatic brain injury |
US20190108912A1 (en) * | 2017-10-05 | 2019-04-11 | Iquity, Inc. | Methods for predicting or detecting disease |
TW202019425A (zh) * | 2018-07-20 | 2020-06-01 | 德商馬克專利公司 | 利用經取代胺基-嘧啶化合物治療及預防多發性硬化症之方法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6077851A (en) * | 1998-04-27 | 2000-06-20 | Active Biotech Ab | Quinoline derivatives |
HUE028833T2 (en) * | 2004-09-09 | 2017-01-30 | Yeda Res & Dev | Polypeptide mixtures, compositions containing them, process for their preparation, and applications |
WO2007146331A1 (en) * | 2006-06-12 | 2007-12-21 | Teva Pharmaceutical Industries, Ltd. | Tannate salt form of polypeptide mixtures, their preparation and use |
EA201270041A1 (ru) * | 2009-06-19 | 2012-06-29 | Тева Фармасьютикал Индастриз Лтд. | Лечение рассеянного склероза лаквинимодом |
WO2011086470A1 (en) * | 2010-01-13 | 2011-07-21 | Ramot At Tel-Aviv University Ltd | Treatment of multiple sclerosis |
JP2014530821A (ja) * | 2011-10-12 | 2014-11-20 | テバ ファーマシューティカル インダストリーズ リミティド | ラキニモドおよびフィンゴリモドを組み合わせた多発性硬化症の治療 |
CN105163737A (zh) * | 2013-02-15 | 2015-12-16 | 梯瓦制药工业有限公司 | 用拉喹莫德治疗多发性硬化症 |
-
2013
- 2013-04-29 TW TW102115308A patent/TW201347762A/zh unknown
- 2013-04-29 TW TW106117959A patent/TW201804997A/zh unknown
- 2013-04-29 AR ARP130101459A patent/AR090885A1/es unknown
- 2013-04-30 UY UY0001034775A patent/UY34775A/es not_active Application Discontinuation
- 2013-05-01 EP EP13784231.6A patent/EP2844255A4/en not_active Withdrawn
- 2013-05-01 SG SG11201406594UA patent/SG11201406594UA/en unknown
- 2013-05-01 MX MX2014013039A patent/MX2014013039A/es unknown
- 2013-05-01 JP JP2015510436A patent/JP2015515985A/ja not_active Withdrawn
- 2013-05-01 WO PCT/US2013/039090 patent/WO2013166166A1/en active Application Filing
- 2013-05-01 CN CN201610240473.8A patent/CN105832733A/zh active Pending
- 2013-05-01 AU AU2013256352A patent/AU2013256352A1/en not_active Abandoned
- 2013-05-01 PE PE2014001911A patent/PE20150161A1/es not_active Application Discontinuation
- 2013-05-01 CN CN201380022530.XA patent/CN104284663A/zh active Pending
- 2013-05-01 US US13/874,537 patent/US20130303569A1/en not_active Abandoned
- 2013-05-01 KR KR1020147033707A patent/KR20150013658A/ko not_active Application Discontinuation
- 2013-05-01 BR BR112014027010A patent/BR112014027010A2/pt not_active IP Right Cessation
- 2013-05-01 EA EA201492010A patent/EA201492010A1/ru unknown
- 2013-05-01 CA CA2870684A patent/CA2870684A1/en not_active Abandoned
-
2014
- 2014-10-26 IL IL235337A patent/IL235337A0/en unknown
- 2014-10-29 CL CL2014002935A patent/CL2014002935A1/es unknown
- 2014-10-31 PH PH12014502447A patent/PH12014502447A1/en unknown
- 2014-12-02 ZA ZA2014/08820A patent/ZA201408820B/en unknown
-
2015
- 2015-06-05 US US14/731,971 patent/US20150265592A1/en not_active Abandoned
- 2015-07-16 HK HK15106789.5A patent/HK1206246A1/xx unknown
- 2015-09-15 US US14/854,849 patent/US20160000775A1/en not_active Abandoned
-
2017
- 2017-07-21 JP JP2017141409A patent/JP2017222691A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
ZA201408820B (en) | 2016-06-29 |
MX2014013039A (es) | 2015-02-04 |
PE20150161A1 (es) | 2015-02-22 |
WO2013166166A1 (en) | 2013-11-07 |
TW201347762A (zh) | 2013-12-01 |
PH12014502447A1 (en) | 2015-01-12 |
US20130303569A1 (en) | 2013-11-14 |
EP2844255A1 (en) | 2015-03-11 |
SG11201406594UA (en) | 2014-11-27 |
IL235337A0 (en) | 2014-12-31 |
JP2017222691A (ja) | 2017-12-21 |
US20150265592A1 (en) | 2015-09-24 |
BR112014027010A2 (pt) | 2017-06-27 |
TW201804997A (zh) | 2018-02-16 |
KR20150013658A (ko) | 2015-02-05 |
CN105832733A (zh) | 2016-08-10 |
CN104284663A (zh) | 2015-01-14 |
EA201492010A1 (ru) | 2015-06-30 |
AU2013256352A1 (en) | 2014-11-27 |
CL2014002935A1 (es) | 2015-03-06 |
CA2870684A1 (en) | 2013-11-07 |
AR090885A1 (es) | 2014-12-10 |
UY34775A (es) | 2013-11-29 |
US20160000775A1 (en) | 2016-01-07 |
JP2015515985A (ja) | 2015-06-04 |
EP2844255A4 (en) | 2015-10-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1206246A1 (en) | Use of high dose laquinimod for treating multiple sclerosis (laquinimod) | |
HRP20180939T1 (hr) | Kombinirana terapija za liječenje multiple skleroze | |
HK1206937A1 (en) | Methods of administering pirfenidone therapy | |
SI2857019T1 (sl) | Postopek zdravljenja multiple skleroze | |
IL234813A0 (en) | Methods for increasing the efficacy of cd37-based therapy | |
PL2812013T3 (pl) | Formulacja do leczenia ibs | |
PL3524260T3 (pl) | Kompozycje farmaceutyczne do leczenia braku apetytu | |
ZA201408062B (en) | Compositions and methods for the treatment of multiple sclerosis | |
PL2938350T3 (pl) | Formulacja medyczna do leczenia hipercholesterolemii | |
EP2897607A4 (en) | BETA-HYDROLASE INHIBITORS FOR THE TREATMENT OF CANCER | |
IL236718A (en) | Vegfr-3 inhibitors for the preparation of drugs for the treatment of liver carcinoma | |
IL244620A0 (en) | A drug combination including laquinimod for the treatment of multiple sclerosis | |
HK1210421A1 (en) | Use of pregn-4-en-20-yn-3-one for the treatment of depressive disorders -4--20--3- | |
HK1206633A1 (en) | Composition for treatment of warts | |
EP2800763A4 (en) | COMPOSITIONS AND METHODS FOR TREATING MULTIPLE SCLEROSIS | |
HUE039044T2 (hu) | Gyógyászati kompozíció sclerosis multiplex kezelésére | |
IL228464A (en) | Quinolone analogues for use in the preparation of MS drugs |